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Summary
 
It has been proposed that the generally low affinities of T cell receptors (TCRs) for their pep-
 
tide–major histocompatibility complex (pMHC) ligands (K
 
d 
 
z
 
10
 
2
 
4 
 
to 10
 
2
 
7
 
 M) are the result of
biological selection rather than an intrinsic affinity limitation imposed by the TCR framework.
Using a soluble version of the 2C TCR, we have used complementarity determining region
(CDR)-directed mutagenesis to investigate whether the affinity of this receptor for its alloge-
neic pMHC ligand can be improved upon. We report that several mutants at positions lying
within CDR3
 
a
 
 and CDR2
 
b
 
 showed increased affinities for pMHC compared with the wild-
type receptor. Additionally, we have investigated whether V
 
a
 
 mutations that have been impli-
cated in the phenomenon of CD8
 
1
 
 repertoire skewing achieve this skewing by means of gen-
eralized increases in affinity for MHC-I molecules. Two mutants (S27F and S51P), which each
promote skewing toward a CD8
 
1
 
 phenotype, exhibited significantly reduced affinity for
pMHC-I, consistent with a quantitative-instructional model of CD4/CD8 lineage commit-
ment. This model predicts that CD8 is downregulated on thymocytes that have TCR–ligand
interactions above a minimal energy threshold. Together, the results (a) demonstrate that engi-
neering higher affinity TCRs is feasible, and (b) provide TCR–pMHC energy values associated
with CD4/CD8 repertoire skewing.
Key words: T cell receptor • peptide–major histocompatibility complex • afﬁnity • CD4/
CD8 • complementarity determining region
 
A
 
ntibodies exhibit structural similarity to TCRs and
undergo similar gene rearrangement processes, yet
they generally exhibit much higher affinities for their anti-
gens (K
 
d 
 
z
 
10
 
2
 
7 
 
to 10
 
2
 
12
 
 M) than do TCRs for their pep-
 
tide–MHC complex (pMHC)
 
1
 
 ligands (K
 
d 
 
z
 
10
 
2
 
4 
 
to 10
 
2
 
7
 
 M)
(1). Although the molecular explanation for these differ-
ences could be that somatic mutation does not operate on
the TCR, there are likely functional explanations also. For
example, negative selection acts to eliminate high TCR af-
finities. In addition, it has been hypothesized that there
may be a ceiling on useful TCR–pMHC affinity (
 
z
 
10
 
2
 
7
 
M), above which there is no functional advantage (2, 3)
(and above which are possibly disadvantages, due to im-
paired serial triggering of TCRs [4]). Antibodies, which
undergo affinity maturation, may have different functional
ceilings on their affinity optimization (5).
Another possibility is that the framework regions of anti-
body V regions are more optimally suited as a scaffold on
which optimal-affinity CDR regions may be constructed,
and that TCR framework regions are handicapped in this re-
gard. Although the three-dimensional structures are similar,
important differences have been observed in the overall sur-
face topology of antibodies compared with at least the 2C
TCR (6). If the low affinities observed for TCR–pMHC in-
teractions are a result of a selection process rather than inher-
ent structural differences, then it should be possible to im-
prove this affinity through CDR-directed mutagenesis.
Using the 2C TCR system, we have explored the possi-
bility of engineering soluble TCR molecules with im-
proved affinities for the allogeneic ligand QL9/L
 
d
 
. Previous
work involving alanine scanning mutagenesis of the 2C
CDR regions revealed four residues that yielded moderate
improvements in affinity when changed to alanine (7). In
 
1
 
Abbreviations used in this paper:
 
 
 
DD
 
G, free energy change; MCMV, mu-
rine CMV; pMHC, peptide–MHC complex; scTCR, single-chain TCR;
SPR, surface plasmon resonance. 
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this report, these mutations have been combined into dou-
ble and triple mutant TCRs to test whether the affinity of
the 2C TCR for its allogeneic ligand QL9/L
 
d
 
 can be fur-
ther improved. This interaction has the highest affinity of
TCR–pMHC interactions that have been measured (K
 
d
 
 5
 
10
 
2
 
7
 
 M [8]). Engineering a higher affinity TCR–QL9/L
 
d
 
interaction would support the notion that a ceiling on
measured TCR–pMHC interactions is imposed by biolog-
ical processes rather than an intrinsic inability of the TCR
framework to support higher affinities. Additionally, solu-
ble TCR molecules with improved affinities could theoret-
ically serve as antagonists for detrimental T cell responses.
We report here that a two- to threefold increase in TCR
affinity could be achieved through CDR-directed mu-
tagenesis.
Another aspect of TCR–pMHC affinity relates to the
process of CD4/CD8 phenotype selection. The 2C TCR
is invariably skewed toward the CD8 phenotype, consistent
with findings that this TCR is positively selected by a class
I MHC product, K
 
b
 
 (9). However, the 2C TCR is some-
what unusual in that it expresses the V
 
a
 
3.1 region, which
has been shown by Gascoigne and colleagues to skew poly-
clonal populations of T cells toward the CD4 phenotype
(13). In fact, various TCR V
 
a
 
 region genes have now been
associated with CD4/CD8 repertoire selection (10–15),
presumably because these V
 
a
 
 chains preferentially bind to
either an MHC class II or class I restricting element. In the
case of the most thoroughly studied family, V
 
a
 
3, the phe-
nomenon is apparently dependent on two amino acid resi-
dues, at position 27 in CDR1 and position 51 in CDR2.
Either residue is sufficient to affect the CD4/CD8 balance,
and together they have an additive effect (13, 14). V
 
a
 
3.2 is
strongly skewed toward the CD8 phenotype and has
Phe
 
27
 
a
 
 and Pro
 
51
 
a
 
 at these positions, whereas V
 
a
 
3.1 is re-
ciprocally skewed toward CD4 and has Ser
 
27
 
a
 
 and Ser
 
51
 
a
 
.
Thus, it was proposed that V
 
a
 
3.2 interacts “preferentially”
with MHC class I molecules and that the skewing attrib-
uted to positions 27 and 51 might result from increased
positive selection (13). It is interesting to note that V
 
a
 
11.3
also contains a proline at position 51 and, like V
 
a
 
3.2, is
skewed toward the CD8 phenotype (15).
Structural analysis of the 2C TCR places both Ser
 
27
 
a
 
 and
Ser
 
51
 
a
 
 in contact with the 
 
a
 
 helices of MHC class I. This
has led to the suggestion that they may play a key role in
orienting the TCR–pMHC interaction (16). One of these
interactions (Ser
 
51
 
a
 
 with the 
 
a
 
2 helix) is also present in the
A6/HLA-A2/Tax structure (17). The binding energetics
associated with the preferential interaction of these two res-
idues with either MHC class I or II molecules has yet to be
elucidated. While the intuitive explanation might predict
that the skewing phenomenon resulted from an increase in
affinity (e.g., of V
 
a
 
3.2 for MHC class I) that favored posi-
tive selection, this has not been proven. In this study, we
have tested the hypothesis that the CD8/CD4 repertoire
skewing attributed to these two residues is accomplished by
increases in affinity for MHC class I molecules. Unexpect-
edly, we found that single or double mutants at these two
positions exhibited affinities that were not consistent with a
 
simple affinity model of increased positive selection, but
rather support the quantitative-instructional model of lin-
eage commitment.
 
Materials and Methods
 
Single-chain TCR Mutagenesis.
 
CDR mutant single-chain
(sc)TCRs were constructed using a PCR-based technique (18).
In brief, a short mutagenic primer and a V
 
a
 
- or V
 
b
 
-specific
primer were used in the first PCR step to generate a “mega-
primer,” which was then isolated and used in a second PCR with
the opposing V
 
a
 
- or V
 
b
 
-specific primer. All PCR reactions were
carried out using cloned 
 
Pfu
 
 DNA polymerase (Stratagene). After
the second PCR, the KpnI-BamHI–digested product was ligated
into pUC-19M and transformed into DH5
 
a
 
 or NM522 
 
Esche-
richia coli
 
 strains for sequencing. After confirmation of the se-
quence, the scTCR gene was subcloned into the pTRXFus vec-
tor (Invitrogen) and transformed into the GI698 
 
E
 
.
 
 coli
 
 strain for
expression.
 
scTCR Expression and Purification.
 
Proteins were expressed in
 
E
 
.
 
 coli
 
 as described previously (7, 19) and purified from inclusion
bodies by denaturing metal affinity chromatography and G-200
size exclusion chromatography. Protein purity was assessed by
SDS-PAGE as well as by electrospray mass spectrometry for sev-
eral of the mutants (performed at the University of Illinois Mass
Spectrometry Facility).
 
mAbs.
 
KJ16 (20) is a rat IgG mAb that is specific for the
mouse V
 
b
 
8.1 and V
 
b
 
8.2 regions. F23.1 (21) is a mouse IgG2a
mAb that is specific for the mouse V
 
b
 
8.1, V
 
b
 
8.2, and V
 
b
 
8.3 re-
gions. F23.2 (21) is a mouse IgG1 mAb that is specific for the
mouse V
 
b
 
8.2 region. 1B2 is an anticlonotypic mouse mAb that is
specific for the 
 
a
 
/
 
b
 
 TCR found on the T cell clone 2C (22).
30-5-7 (23) is a mouse IgG2a mAb that is specific for the 
 
a
 
2 do-
main of H2-L
 
d
 
. Antibodies were purified from either culture
supernatants or ascites. Fab fragments of 30-5-7 were produced
by digestion with papain (Sigma) for 5 min at 37
 
8
 
C followed by
size exclusion chromatography through a Superdex G-200 col-
umn. Residual intact mAb or Fc regions were removed by pas-
sage over a protein A–agarose column (GIBCO BRL).
 
ELISAs.
 
V
 
b
 
8-specific competition ELISAs were performed
by adsorption of KJ16, F23.1, or F23.2 to the wells of Immulon 2
ELISA plates (Dynatech Labs). Wells were blocked with PBS,
0.25% BSA, 0.05% Tween and after washing, 100 
 
m
 
l of mutant
or wild-type TCR and 50 
 
m
 
l of biotinylated wild-type TCR at a
1:1,000–1:3,000 dilution were added to the wells. After 30 min,
wells were washed, and binding was detected using horseradish
peroxidase–streptavidin and TMB peroxidase substrate (Kirke-
gaard & Perry Labs). Inhibition curves were plotted, and the IC
 
50
 
for each mutant and wild-type were calculated using linear re-
gression analysis. For 1B2 capture ELISAs, 1B2 was adsorbed to
wells and after washing, 50 
 
m
 
l of mutant or wild-type TCR was
added to wells. Bound TCR was detected with KJ16 and goat
anti–rat horseradish peroxidase conjugate (Kirkegaard & Perry
Labs).
 
Peptide–MHC Binding Assays.
 
A competition, cell binding
assay was used to monitor binding of TCR to QL9/L
 
d
 
 com-
plexes, as described previously (7, 24, 25). To form peptide–L
 
d
 
complexes on the surfaces of T2-L
 
d
 
 target cells, cells were incu-
bated with 
 
z
 
10 
 
m
 
M of the specific peptide for 3–5 h. For the
competitive binding assay, peptide-upregulated cells (3 
 
3 
 
10
 
5
 
/
well) were incubated with 0.7 nM 
 
125
 
I-labeled 30-5-7 Fab and
various concentrations of scTCR for 1 h on ice in the presence of
0.7% BSA. After incubation, bound and free ligands were sepa- 
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Figure 1. Location of amino acid residues in the 2C TCR that were mutated in this study. The 2C CDR loops are shown interacting with the allo-
antigen QL9/Ld. The 2C/QL9/Ld modeled complex is from reference 26.
 
rated by centrifugation through dibutyl phthalate/olive oil. All
assays were done in triplicate. The cell binding assay was able to
detect binding that was 15–20-fold reduced compared with wild-
type.
All surface plasmon resonance (SPR) measurements were per-
formed on a BIAcore 2000 instrument (BIAcore) at 25
 
8
 
C in PBS.
Purified molecules were immobilized on a CM5 chip at pH 5.2
in 10 mM sodium acetate buffer by classical amine coupling
chemistry. Blank surfaces were made by ethanolamine deactiva-
tion of a dextran surface. Purified L
 
d
 
–peptide complexes were in-
jected at 6, 3, 1.5, 0.75, and 0.375 
 
m
 
M at a flow rate of 20 
 
m
 
l/
min. Data were normalized and analyzed using the BIAevaluation
2.1 and 3.0 software programs (BIAcore). Single Langmuir bind-
ing model was used for curve fitting analysis. Fittings were as-
sessed by K2 function (
 
,
 
5.0). Baseline drift between successive
injections was 
 
,
 
2%. Scatchard analyses were plotted from sub-
tracted sensorgrams (L
 
d
 
-QL9 minus Ld-murine CMV [MCMV]
traces). Binding studies were performed with immobilized TCR
proteins and the reverse orientation with immobilized Ld–peptide
complexes.
Statistical Analysis of Binding Data. The percent inhibition of
T2-Ld binding was corrected for the binding of 125I-labeled 30-5-7
Fab fragments to Ld molecules which do not contain the pep-
tide of interest, as follows: % inhibition 5 (cpmQL9, no TCR 2
cpmQL9, 1TCR) / (cpmQL9, no TCR 2 cpmno peptide) 3 100. Inhibition
curves were constructed, and within each experiment a sample of
wild-type scTCR was included as an internal control. QL9/Ld
reactivity was calculated as the IC50(mutant)/IC50(wild-type), and was
normalized for Vb8 reactivity to account for variations in the
percentages of properly folded proteins.
Structural Analysis. Structural analysis was performed on an
Indigo 2 workstation (Silicon Graphics) using the Quanta soft-
ware package (Molecular Simulations). The refined structure of
the 2C/dEV8/Kb complex (16) was used to assign pMHC con-
tacts for those 2C residues tested by mutagenesis.
Results
Recently, we have mapped the energy of interactions of
2C TCR residues by performing alanine scanning mu-
tagenesis of the 2C TCR and analyzing the mutants for
binding to QL9/Ld (7). The mutagenesis study revealed
four residues (Glu56b, Thr55b, Ser76b, Ser102a) that, when
changed to alanine, exhibited increases (up to twofold) in
affinity for QL9/Ld. Two other residues (Ser27a and Ser51a)
are also thought to play a significant role in the binding of
the class I ligand. This prediction is based both on the con-
tact of these residues with conserved residues in the MHC
helices (16) and on their effects on skewing of T cells to a
CD4 or CD8 phenotype (13, 14). These six residues are
shown in Fig. 1, where the 2C TCR is modeled onto the
QL9/Ld ligand based on coordinates of the 2C/dEV8/Kb
complex (26). To explore various issues that involve the
binding contributions of these residues, mutagenesis was
performed and the two classes of mutants (alanine-substitu-
ent affinity mutants and CD4/CD8 repertoire-skewing
mutants) were analyzed for binding to anti-TCR antibod-
ies and to the pMHC ligand QL9/Ld.464 CDR Affinity Mutants of an a/b TCR
TCR Mutagenesis, Expression, and Purification
The Va3.1/Vb8.2 TCR from CTL clone 2C has been
produced as a single-chain thioredoxin fusion protein in E.
coli for use in binding and mutagenesis studies (7, 24, 25, 27).
Various single, double, and triple mutants involving six resi-
dues (Glu56b, Thr55b, Ser76b, Ser102a, Ser27a, and Ser51a) were
generated using a two-step PCR–based approach. Mutants
were subjected to automated DNA sequencing to confirm
mutations. TCRs were expressed in E. coli and purified by
metal affinity and size exclusion chromatography to $95%
purity. Electrospray mass spectrometry was used to confirm
the expected mass difference relative to wild-type for several
of the mutant TCRs (Fig. 2). The wild-type scTCR is evi-
dent as a single peak of mass 40,538 6 4 daltons (0.01% ac-
curacy), whereas the various mutant TCRs exhibit mass dif-
ferences equivalent to those predicted based on their amino
acid differences. This sensitive method is able to confirm the
mass difference attributable to the loss of as little as a single
oxygen atom in an z40,000-dalton protein, as demonstrated
with the aS27A mutant (Fig. 2).
Alanine-substituent Affinity Mutants
The four single-site alanine mutants of TCR residues
(Glu56b, Thr55b, Ser76b, Ser102a) that exhibited modest increases
in affinity for QL9/Ld (7) were examined as double and triple
alanine mutants to test whether synergistic affinity increases
might be achieved. In addition, residue 56b was changed to a
positive charge (Lys56b) to test the possibility that this glutamic
acid side chain in the wild-type is near a negatively charged
residue in the ligand and thus that a positive charge at residue
56b may yield even higher affinity for QL9/Ld.
Antibody Reactivity. The degree to which each mutant
was properly refolded was analyzed using the mAbs KJ16
(Vb8.1/8.2 specific) and F23.1 (Vb8.1/8.2/8.3 specific).
These two mAbs recognize determinants on the TCR dis-
tal from the CDR regions. Each of the mutants exhibited
essentially the same reactivity as wild-type (Fig. 3 A, and
data not shown), indicating that the mutant TCRs have the
same degree of refolding as wild-type, and confirming that
mutations have not globally disrupted the protein’s tertiary
conformation. Thus, any differences observed in reactivi-
ties of the mutants toward other antigens can be attribut-
able to the role of the substituted amino acid and not to a
global destabilization of the receptor.
The mAb F23.2 is specific for Vb8.2, and its epitope has
been shown to include residue Glu56b, which is critical for
binding (7). The reactivity of each mutant was analyzed in
F23.2 competition ELISA experiments where it was con-
firmed that those mutants containing the bE56A mutation
(i.e., 102/56, 102/56/76, 56/76, E56A, or E56K) reduced
binding to F23.2 by at least 100-fold ($2.5 kcal/mol). Ala-
nine substitution at Thr55b exerts only a moderate effect
(three- to fourfold reduction) on F23.2 binding (7). As ex-
pected, this moderate reduction in affinity is also observed
in the T55A-containing mutants (i.e., 102/55, 55/76, 102/
55/76, and T55A; Fig. 3 B, and Fig. 4). Thus, mAb F23.2
serves as an additional probe of the tertiary conformation of
the scTCR mutants.
The clonotypic antibody 1B2 recognizes an epitope on
the 2C TCR which overlaps with the pMHC epitope (7).
Therefore, it was of interest to determine the effect of dou-
ble and triple alanine mutations on 1B2 binding. Similar to
the effect observed with F23.2, each of the mutants that
Figure 2. Mass spectrometry of scTCR CDR mutants. Purified wild-
type (WT) and mutant TCR proteins were dialyzed into 30% acetonitrile,
0.1% formic acid and subjected to mass spectrometry. Sensitivity of mea-
surement was generally 64 daltons (i.e., 0.01%). Observed mass differences
attributable to the amino acid substitutions are shown. Expected mass dif-
ferences (in daltons) were as follows: S51P, 110; S27A, 216; S27F, 160.
Figure 3. Analysis of higher affinity alanine-substituent 2C TCR dou-
ble mutants. Representative binding curves are illustrated for each of the
different ligands for the 102/55, 102/56, and wild-type (WT) scTCR
proteins. ELISA binding curves are presented for the mAbs F23.1 (Vb8.1,
8.2, 8.3; A) and F23.2 (Vb8.2; B), as well as the clonotypic mAb 1B2 (C).
Inhibition of 30-5-7 (anti-Ld) Fab binding to cell surface QL9/Ld is
shown in D.465 Manning et al.
contained an E56 mutation had at least a 20-fold reduction
in 1B2 activity (Fig. 3 C, and Fig. 4). The S102A mutant
exhibited a more moderate fivefold reduced 1B2 activity,
whereas T55A had threefold reduced activity. The combi-
nation of these two mutants in a single protein resulted in
an approximately additive effect on binding (i.e., 11-fold
reduced binding activity for either 102/55 or 102/55/76).
Consistent with the observation that Ser76b is not involved
in either the F23.2 or 1B2 epitopes (7), no additional effect
on reactivity was observed with double or triple mutants
that involved this position.
Peptide–MHC Reactivity. To assess the effect of alanine-
substituent mutations on pMHC recognition, mutants
were tested for the ability to inhibit binding of 125I-labeled
anti-Ld Fab fragments to the QL9/Ld alloantigen. In con-
trast to the significant impairments seen in F23.2 and 1B2
antibody reactivity, all of the alanine-substituent mutants
bound to pMHC at least as well as the wild-type scTCR
(Fig. 3 D, and Fig. 4). The greatest improvement in
pMHC recognition was achieved with the 102/55 double
mutant, which was 2.3-fold better than wild-type (free en-
ergy change [DDG] 5 20.44 kcal/mol). The effect ob-
served with 102/55 appears to have been at least partially
additive, in that S102A and T55A had DDG values of
20.31 and 20.23 kcal/mol, respectively. In contrast, the
effect seen with 102/56 (DDG 5 20.32 kcal/mol) is only a
slight improvement on the binding energy of the S102A
single mutant (S102A and E56A have DDGs of 20.31 and
20.11 kcal/mol, respectively).
Residue Ser76b is within the HV4 loop and does not in-
teract with antigen in the refined 2C/dEV8/Kb structure
(16). Consequently, the modest improvement in pMHC
affinity initially observed with S76A was attributed to indi-
rect effects (7). In this study, the effects of the S76A muta-
tion when paired with other mutations was variable. The
55/76 mutant appeared to bind pMHC marginally better
than T55A, but incorporation of an S76A mutation re-
duced the affinity of 102/55, 102/56, and E56A (Fig. 4).
Thus, whatever indirect conformational effects S76A
makes on its own to increase affinity do not appear to be
readily accommodated in the presence of other mutations.
In the model of the 2C TCR–QL9/Ld complex, residue
Glu56b is positioned 9 Å opposite Glu 71 of the Ld a1 helix.
We suggested that this pairing might represent an unfavor-
able electrostatic interaction (7). We reasoned that intro-
duction of a positively charged lysine residue at position
56b might create a more favorable electrostatic pairing of
the 2C and QL9/Ld surfaces. In contradiction to this no-
tion, the E56K mutant exhibited significantly decreased
binding to QL9/Ld (DDG 5 1.06 kcal/mol). Thus, simple
introduction of a positive charge at this position does not
create a more favorable electrostatic interaction between
the TCR and pMHC.
Kinetics of Alanine-substituent Mutants. Since the greatest
improvement in binding affinity was achieved with the
102/55 double mutant, we sought to investigate the kinetic
parameters involved in its binding to pMHC. Using immo-
bilized mutant TCRs, binding to soluble pMHC com-
plexes was analyzed by BIAcore SPR. The 102/55 double
mutant was found to have on and off rates which were
both slowed compared with wild-type (Fig. 5). The on and
off rates for wild-type were 2.4- and 3.2-fold faster, respec-
tively, than the rates for 102/55 (Fig. 5). The relatively
larger difference observed for the off rates translates into a
23% lower overall equilibrium dissociation constant for
102/55 compared with wild-type, consistent with results
from the Fab inhibition experiments. The reverse orienta-
tion, with biotinylated Ld–peptide complexes immobilized
on the chip, yielded similar kinetic differences between the
wild-type and 102/55 TCR (data not shown). In addition,
the Kd values of the two proteins differed by 1.3–2.7-fold
using three different methods of BIAcore analysis: (a) by
kinetic measurements with immobilized TCR, Kd of wild-
type TCR 5 3.2 mM and of 102/55 TCR 5 2.4 mM (Fig.
5); (b) by kinetic measurements with immobilized Ld–pep-
tide, Kd of wild-type TCR 5 1.9 mM and of 102/55 TCR 5
Figure 4. Summary binding data for alanine-substituent mutants ana-
lyzed in this study. Free energy changes for F23.2 (top) and QL9/Ld (bot-
tom) binding were calculated from competition experiments using
IC50(mutant)/IC50(wild-type) and were normalized for KJ16/F23.1 reactivity to
account for slight variations in sample refolding and purity. 1B2 reactivity
(middle) was determined from a capture ELISA format, with the concen-
tration of scTCR yielding 50% maximal signal used analogously to IC50.
DDG values .0 indicate decreased binding.466 CDR Affinity Mutants of an a/b TCR
0.7 mM (data not shown); and (c) by Scatchard analyses of
binding at various Ld–peptide concentrations, Kd of wild-
type TCR 5 1.9 mM and of 102/55 TCR 5 1.2 mM (data
not shown). These results, together with data from the cell
binding assay described above, indicate that the 102/55
mutant has a higher affinity that the wild-type.
CD4/CD8 Repertoire-skewing Mutants
Previous work has suggested that a phenylalanine at posi-
tion 27 (in CDR1) and a proline at position 51 (in CDR2)
within the Va3.2 region may each interact with MHC class
I, thereby accounting for the tendency of Va3.21 T cells to
skew toward a CD8 phenotype (13). To test the hypothesis
that this preferential interaction involves an increase in affin-
ity for MHC class I, we constructed mutant 2C scTCRs in-
corporating these “Va3.2-like” substitutions into the 2C
Va3.1 region (see Table I). Additionally, we also analyzed
alanine-substituent mutants at these two positions.
Antibody Reactivity. Each of these Va3.2-like mutants
exhibited equivalent reactivity to wild-type in KJ16, F23.1,
and F23.2 ELISAs, indicating the same degree of refolding
(Fig. 6 A, and data not shown). Alanine substitution at either
position did not affect recognition by 1B2, but S27F exhib-
ited a slight increase in reactivity toward 1B2 and S51P had
z60-fold reduced 1B2 reactivity (data not shown). The fail-
ure of these mutations to affect F23.2, KJ16, and F23.1 reac-
tivity confirms that there has not been a global effect on
TCR conformation, beyond the a chain CDR regions.
Figure 5. SPR analysis and
comparison of wild-type and
102/55 TCR mutants. QL9/Ld
complexes bind both TCRs
compared with MCMV–Ld com-
plexes (A–C). The higher affinity
of the double mutant is due to a
differential slowing of both its off
rate (D and F) and its on rate (D
and E) compared with the wild-
type (WT). Similar results were
obtained in the reverse orienta-
tion (immobilized Ld-QL9).467 Manning et al.
Peptide–MHC Reactivity. In both the 2C/dEV8/Kb struc-
ture and the 2C/QL9/Ld model, serines 27 and 51 are each
involved in hydrogen bonding to conserved residues on the
a helices (Fig. 1). We have previously reported that elimi-
nation of the hydroxyl moiety of Ser51a does not have an
effect on recognition of the allogeneic pMHC ligand (7).
Elimination of the hydroxyl at Ser27a similarly failed to dis-
rupt binding to QL9/Ld (Fig. 6, B and C). Together, these
data suggest that the amount of binding energy contributed
by these two hydrogen bonds is negligible in the interac-
tion of 2C with the Ld alloantigen.
In contrast to our expectations, substitution of a phenyla-
lanine for the serine at position 27 in CDR1 resulted in a
mutant that had 1.6-fold reduced binding to pMHC (DDG 5
0.24 kcal/mol; Fig. 6, B and C). Furthermore, the aS51P
mutant in CDR2 exhibited z15-fold reduced binding to
pMHC (DDG 5 1.5 kcal/mol). Combination of both
mutations yielded approximately additive effects on both
QL9/Ld binding (Fig. 6 C) and 1B2 binding (data not
shown). The pMHC affinity of the S27F/S51P Va3.2-like
double mutant was below the detection limits of the cellu-
lar binding assay. Together, these results illustrate that the
Va3.2 mutations do not result in a general enhancement of
binding to MHC class I molecules.
Discussion
This study addressed two questions of immunological
significance regarding the binding of a TCR to its class I
ligand. First, is it possible to use site-directed mutagenesis
of CDR residues to increase the affinity of a TCR? Sec-
ond, do various TCR mutants in Va residues involved in
repertoire skewing of a TCR toward the CD8 phenotype
exhibit correlative affinities for the class I ligand?
The TCR from the alloreactive clone 2C could be used
to address each of these questions. The 2C–QL9/Ld inter-
action represents the highest affinity TCR–pMHC interac-
tion that has been measured (8), and our recent alanine
scanning study identified several residues that might serve
as the starting point for the rational design of higher affinity
TCR mutants (7). To examine if TCR affinity could be
improved, we concentrated on the four CDR positions
initially found to have very modest increases in affinity
when mutated to alanine. Thus, alanine mutants at posi-
tions Ser102a, Thr55b, Glu56b, and Ser76b were combined as
either double or triple mutants. Since Thr55b and Glu56b are
adjacent to each other in the refined 2C/dEV8/Kb struc-
ture, it was thought that they might be achieving their ef-
fect via similar mechanisms, and the 55/56 double mutant
was not generated. Additionally, since elimination of the
negative charge at position 56 seemed energetically favor-
able, the charge reversal mutant E56K was analyzed. Re-
sults of antibody reactivity of the various multiple alanine
mutants were entirely consistent with the results from sin-
gle mutants (e.g., each of the position 56 mutants had
greatly reduced F23.2 binding), and also demonstrated that
the mutants had equivalent refolding as measured by KJ16
and F23.1 (Figs. 3 A and Fig. 4, and data not shown).
The greatest increase in affinity for pMHC was observed
with combined alanine substitution at positions Ser102a and
Thr55b (i.e., 102/55), which exhibited an approximately
twofold increase in affinity over wild-type and had slower
association and dissociation kinetics than wild-type. The
mechanism behind this increase in affinity is not clear, but
based on structural analysis several possibilities exist. First,
modeling of the 2C/QL9/Ld complex places Ser102a in a
position of steric clash with ProP6 (26). Elimination of the
hydroxyl moiety at this position might serve to eliminate or
lessen this steric effect. Second, in the 2C/dEV8/Kb struc-
ture (16), Glu56b lies 9 Å opposite Glu71 of the a1 helix, a
negatively charged residue common to both Kb and Ld that
Table I. Sequence Comparison of CDR1 and CDR2 Regions 
from 2C TCR (Va3.1) and AV3 Gene Family Members
CDR1 CDR2
24 31 48 55
Va3.1 (2C) YSYSATPY KYYSGDPV
Va3.2 (AV3S2) ---FG--- ---P----
Va3.1 (AV3S5) ----G--- --------
AV3 family sequences are from B6 mice. CTL 2C was isolated from a
Balb.B mouse.
Figure 6. Analysis of Va3.2-like TCR mutants. Mutants exhibited
equivalent reactivity toward the Vb8-specific mAb KJ16 (A). Va3.2-like
mutants were impaired in their ability to inhibit 30-5-7 (anti-Ld) Fab
binding to cell surface QL9/Ld (B). Summary data indicate the relative
change in binding free energy for mutant TCR compared with wild-type
(C). Free energy changes were calculated from competition experiments
using IC50(mutant)/IC50(wild-type). Mutants with no detectable binding in the
cell binding assay were assigned DDG values 5 1.5 kcal/mol, the sensitiv-
ity limit of the assay. DDG values .0 indicate decreased binding.468 CDR Affinity Mutants of an a/b TCR
may represent a somewhat unfavorable electrostatic inter-
action surface. Alanine mutation of adjacent residue Thr55b
might allow Glu56b to adopt a less electrostatically impaired
conformation. However, the failure of E56K to improve
pMHC affinity illustrates that the interactions that contrib-
ute to the binding energy of TCR–pMHC are subtle, con-
text dependent, and not necessarily amenable to techniques
such as charge swapping. Previous studies with other pro-
tein–protein interactions have shown similar difficulties in
predicting whether charge complementation pairs might be
successful in this regard.
The potential additivity of the various double and triple
mutants analyzed in this study could not be predicted. This
contrasts with the alanine scanning analysis of growth hor-
mone and its receptor, in which additivity was the rule
(28). This has led many to assume that additivity will be
observed when noninteracting mutations are combined.
However, consistent with our results with the TCR, a re-
cent study to improve the affinity of an anti-HIV gp120
antibody observed unpredictable additivity (only one of six
combinations was additive) when mutations were recom-
bined (29). There is some evidence that a rigorous ac-
counting of bound water molecules in protein–protein in-
teractions can account for certain cases when double
mutants behave in a less than additive manner (30). The
reasons underlying the unpredictable additivity observed in
this study are unclear, but could be related to the presence
of water molecules and poor complementarity of fit ob-
served in the refined structure (16).
Despite the only twofold increase in affinity achieved by
directed site-specific mutagenesis, these results indicate the
promise in using more sophisticated techniques to obtain
even greater improvements in TCR affinity. In fact, the
earliest efforts to engineer higher affinity antibodies yielded
a similar magnitude of increase (31, 32). More recent ap-
proaches have greatly enhanced these efforts (33), and we
predict the same will now be possible with the TCR. This
expectation is also based on the observation that the TCR–
pMHC interaction is marked by poor complementarity of
fit (16). According to an algorithm used to calculate com-
plementarity of fit, the 2C/dEV8/Kb and A6/HLA-A2/
Tax complexes gave values of 0.45 and 0.47, respectively,
whereas most antigen–antibody interactions have values in
the range of 0.66–0.68, and oligomeric proteins in the
range of 0.68–0.75 (16). Clearly, there are regions of the
TCR–pMHC interface where the fit can be improved
through the introduction of amino acid substitutions. Thus,
mutagenesis methods that explore the effects of amino acids
other than alanine could yield still higher affinity soluble
TCRs.
The second aspect of this report concerns the role of
TCR affinity in repertoire skewing of a TCR toward the
CD8 phenotype. The observation that Va3.1 transgenic
mice expressing the mutations S27F and S51P have a rep-
ertoire skewed toward a CD81 phenotype suggested the
notion that these positions contacted the class I selecting el-
ement, and the interaction was described as being preferen-
tial toward class I (13, 14). Structural analysis of the 2C
TCR showed that the serines at positions 27 and 51 of the
a chain contact conserved residues on the class I helices
(16; depicted in Fig. 1). Together, these studies might lead
one to predict (a) that the serines at positions 27 and 51
would contribute some energy to the TCR–pMHC inter-
action, and (b) that substitution of phenylalanine (at posi-
tion 27) and proline (at position 51) would yield even
higher affinity. Surprisingly, neither of these predictions
was borne out in the measurements of binding affinities
described here. Both alanine mutants at position 27 and 51
had negligible effects on the binding of the QL9/Ld ligand.
That is, elimination of either hydroxyl group and the dis-
ruption of that hydrogen bonding capability had no effect
on the equilibrium affinity of the TCR for pMHC. Substi-
tution of the Va3.2 residues (Phe and Pro) yielded not
higher but lower affinities for the QL9/Ld ligand.
What, then, accounts for the apparent discrepancy be-
tween these results and the observed skewing? Serine is the
most frequently occurring amino acid at both positions 27
and 51 in murine Va genes (34). Threonine is also a fre-
quent residue at both these positions, but Phe27a and Pro51a
are found much less often. At position 27, the relative fre-
quency at which these residues are found is as follows:
serine 43%, threonine 22%, phenylalanine 1%. At position
51, serine occurs at 54% frequency, threonine at 25%, and
proline at only 7% (34). Thus, there is conservation of hy-
droxyl-containing amino acids at these positions. Based on
these findings and the 2C/dEV8/Kb structure, it has been
suggested that these serines may help to orient the TCR
diagonally on the pMHC (16). Serine residues at both posi-
tions are also found contacting MHC helices in the recent
B7/Tax/HLA-A2 structure (35). Nevertheless, elimination
of the hydroxyl group at either position failed to signifi-
cantly effect the overall affinity of the 2C–pMHC interac-
tion (Fig. 6). Two possible explanations may account for
these observations. First, although the equilibrium affinity
of the S27A and S51A mutants are unchanged from wild-
type (perhaps due to compensation by bridging water mol-
ecules), it is possible that these hydroxyl residues have a fa-
vorable effect on binding kinetics (e.g., by increasing both
on and off rates). This would be consistent with the kinetic
differences observed for the 102/55 double alanine mutant,
where elimination of two hydroxyl moieties at Ser102a and
Thr55b slowed both the on and off rates. Second, it is possi-
ble that the interaction of the 2C TCR with the QL9/Ld
ligand may differ fundamentally from the interaction of the
2C TCR with the dEV8/Kb ligand. Arguing against this
explanation is the fact that those residues within the Kb a
helices which contact Ser27a and Ser51a (Glu 58 and Arg 62
contacting Ser27a, and Ala 152, Gly 162, and Glu 166 con-
tacting Ser51a) are identical in Ld. If the interaction with Kb
and Ld was in fact fundamentally different, it is conceivable
that Va3.1 and Va3.2 would differ in skewing toward a
CD4 or CD8 phenotype if the selecting environment con-
tained Ld as the only class I molecule.
The possibility that some class I molecules could interact
with the Va3 region in a different manner remains to be
examined, and in this respect it is important to recognize469 Manning et al.
that our findings involve measurements with a single
TCR–pMHC system. Other TCR–pMHC interactions
will no doubt need to be analyzed to support a particular
model of CD4/CD8 skewing. Nevertheless, we believe
our results with the alanine and Va3.2-like substitutions at
positions 27 and 51 are most consistent with the recent
quantitative-instructional model for CD4/CD8 lineage
commitment (36–38). According to this model, gradations
in the intensity of signaling through the TCR complex of
CD41/CD81 thymocytes determines lineage commit-
ment. Signals of strong intensity promote CD4 differentia-
tion, whereas weaker intensity signals promote a CD8 fate.
Consistent with this model, Va3.1 2C (Ser27a and Ser51a)
binds class I with z15-fold higher affinity than Va3.2-like
2C (Phe27a and Pro51a). Consequently, Va3.1 is skewed
toward CD4, whereas Va3.2 is skewed toward CD8.
Thus, it appears that energy changes amounting to as little
as 0.25 kcal/mol (S27F) can skew the lineage commitment
of developing thymocytes. Since 2C is a class I–restricted
TCR, we are unable to address the effect of these muta-
tions on binding to MHC class II. According to the quanti-
tative-instructional model, one might expect that Va3.1
(Ser27a and Ser51a) would contribute to increased affinity
for MHC class II as well as class I. In this regard, the high
frequency of serine residues at these positions (43 and 54%)
is not surprising, since it would then act to promote general
MHC reactivity. However, it is possible that interaction of
thymocytes with class I molecules alone may explain Va3
skewing, since commitment to the CD41 lineage can oc-
cur in the absence of MHC class II molecules and does not
require MHC class II–restricted TCRs (39).
A second, not mutually exclusive, possibility is that dif-
ferential negative selection could also be involved in the
observed CD4/CD8 skewing. According to this mecha-
nism, CD81 thymocytes which express Va3.1 TCRs (i.e.,
possessing Ser27a and Ser51a) could bind selectively to
MHC class I molecules, predisposing them to elimination
by negative selection. CD81 thymocytes which express
Va3.2 TCRs (i.e., Phe27a and Pro51a) would have an in-
herently lower affinity for MHC class I, thereby allowing
them to escape negative selection. Presumably, this process
would operate at the stage of the semimature single-posi-
tive heat stable antigen (HSA)hi thymocyte, a cell type that
remains susceptible to negative selection within the thymic
medulla (40). It has recently been estimated that 20–30% of
thymocytes in mice are susceptible to negative selection
(41), a figure which could easily accommodate a degree of
repertoire skewing by differential negative selection.
In conclusion, we have provided direct evidence that the
TCR framework can be engineered to support higher
affinities for pMHC than are selected for during thymic de-
velopment. Additionally, we have shown that the mecha-
nism whereby two CDR mutants skew the T cell repertoire
toward a CD81 phenotype is not attributable to a general
increase in affinity for MHC class I, but rather is consistent
with predictions from the quantitative-instructional model
of lineage commitment.
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